Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Centessa Pharmaceuticals (CNTA) Income from Continuing Operations (2022 - 2026)

Centessa Pharmaceuticals has reported Income from Continuing Operations over the past 4 years, most recently at 66163000.0 for Q4 2025.

  • Quarterly Income from Continuing Operations rose 40.57% to 66163000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 197532000.0 through Dec 2025, up 16.21% year-over-year, with the annual reading at 197532000.0 for FY2025, 16.21% up from the prior year.
  • Income from Continuing Operations was 66163000.0 for Q4 2025 at Centessa Pharmaceuticals, down from 54891000.0 in the prior quarter.
  • Over five years, Income from Continuing Operations peaked at 24886000.0 in Q2 2023 and troughed at 111329000.0 in Q4 2024.
  • The 4-year median for Income from Continuing Operations is 47079500.0 (2024), against an average of 50038875.0.
  • Year-over-year, Income from Continuing Operations skyrocketed 61.51% in 2023 and then crashed 202.22% in 2024.
  • A 4-year view of Income from Continuing Operations shows it stood at 43173000.0 in 2022, then grew by 14.68% to 36837000.0 in 2023, then crashed by 202.22% to 111329000.0 in 2024, then surged by 40.57% to 66163000.0 in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Income from Continuing Operations are 66163000.0 (Q4 2025), 54891000.0 (Q3 2025), and 50343000.0 (Q2 2025).